Sartorius Stedim Biotech S.A./€DIM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech S.A. specializes in providing equipment and services for the biopharmaceutical industry, focusing on products such as cell lines, cell culture media, bioreactors, and systems for separation, purification, and storage of biological products. Founded in 1978 and headquartered in Aubagne, France, the company operates globally with manufacturing and R&D sites in Europe, North America, and Asia. A subsidiary of Sartorius AG, Sartorius Stedim Biotech has expanded its portfolio through acquisitions, including the 2023 purchase of Polyplus-transfection SA for $2.7 billion. In 2023, the company reported sales revenue of approximately €2.8 billion and employed over 10,600 individuals worldwide. (,)
Ticker
€DIM
Sector
Primary listing
PAR
Employees
10,134
Headquarters
Website
DIM Metrics
BasicAdvanced
€21B
77.98
€2.71
0.89
€0.69
0.33%
Price and volume
Market cap
€21B
Beta
0.89
52-week high
€238.89
52-week low
€148.75
Average daily volume
300
Dividend rate
€0.69
Financial strength
Current ratio
1.054
Quick ratio
0.418
Long term debt to equity
49.444
Total debt to equity
62.937
Dividend payout ratio (TTM)
25.43%
Interest coverage (TTM)
3.32%
Profitability
EBITDA (TTM)
761.8
Gross margin (TTM)
45.64%
Net profit margin (TTM)
8.96%
Operating margin (TTM)
17.49%
Effective tax rate (TTM)
21.22%
Revenue per employee (TTM)
€290,000
Management effectiveness
Return on assets (TTM)
4.06%
Return on equity (TTM)
6.62%
Valuation
Price to earnings (TTM)
77.976
Price to revenue (TTM)
6.984
Price to book
5.1
Price to tangible book (TTM)
-52.61
Price to free cash flow (TTM)
54.948
Free cash flow yield (TTM)
1.82%
Free cash flow per share (TTM)
3.845
Dividend yield (TTM)
0.33%
Forward dividend yield
0.33%
Growth
Revenue change (TTM)
7.72%
Earnings per share change (TTM)
61.10%
3-year revenue growth (CAGR)
-4.48%
10-year revenue growth (CAGR)
13.24%
3-year earnings per share growth (CAGR)
-28.41%
10-year earnings per share growth (CAGR)
8.49%
Bulls say / Bears say
In the first half of 2025, Sartorius Stedim Biotech posted sales revenue of €1.49 billion, up 9.4 percent year-over-year at constant currencies, supported by strong demand for high-margin consumables (Sartorius press release).
The underlying EBITDA margin rose by 2.8 percentage points to 31.0 percent in H1 2025, driven by operational leverage from product mix and volume expansion (Sartorius press release).
The company strengthened its innovation pipeline in H1 2025, introducing two new continuous manufacturing platform modules and a PFAS-free high-throughput filter, which enhanced its competitive edge (Sartorius press release).
Equipment and systems revenue remained subdued in H1 2025, as customers continued to limit capital expenditures, which constrained growth outside the consumables segment (Sartorius press release).
For FY 2024, organic sales fell by 0.7 percent in constant currencies, highlighting a dependence on non-organic sources to support overall revenue (Sartorius press release).
Management’s full-year 2025 revenue outlook of about 7 percent is below the H1 growth of 9.4 percent, suggesting a possible slowdown in the second half of the year (Sartorius press release).
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sartorius Stedim Biotech S.A. stock?
Sartorius Stedim Biotech S.A. (DIM) has a market cap of €21B as of October 27, 2025.
What is the P/E ratio for Sartorius Stedim Biotech S.A. stock?
The price to earnings (P/E) ratio for Sartorius Stedim Biotech S.A. (DIM) stock is 77.98 as of October 27, 2025.
Does Sartorius Stedim Biotech S.A. stock pay dividends?
Yes, the Sartorius Stedim Biotech S.A. (DIM) stock pays dividends to shareholders. As of October 27, 2025, the dividend rate is €0.69 and the yield is 0.33%. Sartorius Stedim Biotech S.A. has a payout ratio of 25.43% on a trailing twelve-month basis.
When is the next Sartorius Stedim Biotech S.A. dividend payment date?
The next Sartorius Stedim Biotech S.A. (DIM) dividend payment date is unconfirmed.
What is the beta indicator for Sartorius Stedim Biotech S.A.?
Sartorius Stedim Biotech S.A. (DIM) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.